MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy

Maria Grazia Rodriquenz; Giandomenico Roviello; Alberto D'Angelo; Daniele Lavacchi; Franco Roviello; Karol Polom

doi:10.3390/jcm9051427

MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy

Maria Grazia Rodriquenz, Giandomenico Roviello, Alberto D'Angelo, Daniele Lavacchi, Franco Roviello, Karol Polom

Research output: Contribution to journal › Review article › peer-review

60 Citations (SciVal)

41 Downloads (Pure)

Abstract

Gastric cancers have been historically classified based on histomorphologic features. The Cancer Genome Atlas network reported the comprehensive identification of genetic alterations associated with gastric cancer, identifying four distinct subtypes- Epstein-Barr virus (EBV)-positive, microsatellite-unstable/instability (MSI), genomically stable and chromosomal instability. In particular, EBV-positive and MSI gastric cancers seem responsive to novel immunotherapies drugs. The aim of this review is to describe MSI and EBV positive gastric cancer's subgroups and their relationship with novel immunotherapy.

Original language	English
Article number	1427
Journal	Journal of Clinical Medicine
Volume	9
Issue number	5
DOIs	https://doi.org/10.3390/jcm9051427
Publication status	Published - 11 May 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/jcm9051427Licence: CC BY

Published paper

Cite this

@article{de1dd45f073b499fb414fea5fbc3a37d,

title = "MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy",

abstract = "Gastric cancers have been historically classified based on histomorphologic features. The Cancer Genome Atlas network reported the comprehensive identification of genetic alterations associated with gastric cancer, identifying four distinct subtypes- Epstein-Barr virus (EBV)-positive, microsatellite-unstable/instability (MSI), genomically stable and chromosomal instability. In particular, EBV-positive and MSI gastric cancers seem responsive to novel immunotherapies drugs. The aim of this review is to describe MSI and EBV positive gastric cancer's subgroups and their relationship with novel immunotherapy.",

author = "Rodriquenz, {Maria Grazia} and Giandomenico Roviello and Alberto D'Angelo and Daniele Lavacchi and Franco Roviello and Karol Polom",

year = "2020",

month = may,

day = "11",

doi = "10.3390/jcm9051427",

language = "English",

volume = "9",

journal = "Journal of Clinical Medicine",

issn = "2077-0383",

publisher = "MDPI",

number = "5",

}

TY - JOUR

T1 - MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy

AU - Rodriquenz, Maria Grazia

AU - Roviello, Giandomenico

AU - D'Angelo, Alberto

AU - Lavacchi, Daniele

AU - Roviello, Franco

AU - Polom, Karol

PY - 2020/5/11

Y1 - 2020/5/11

N2 - Gastric cancers have been historically classified based on histomorphologic features. The Cancer Genome Atlas network reported the comprehensive identification of genetic alterations associated with gastric cancer, identifying four distinct subtypes- Epstein-Barr virus (EBV)-positive, microsatellite-unstable/instability (MSI), genomically stable and chromosomal instability. In particular, EBV-positive and MSI gastric cancers seem responsive to novel immunotherapies drugs. The aim of this review is to describe MSI and EBV positive gastric cancer's subgroups and their relationship with novel immunotherapy.

AB - Gastric cancers have been historically classified based on histomorphologic features. The Cancer Genome Atlas network reported the comprehensive identification of genetic alterations associated with gastric cancer, identifying four distinct subtypes- Epstein-Barr virus (EBV)-positive, microsatellite-unstable/instability (MSI), genomically stable and chromosomal instability. In particular, EBV-positive and MSI gastric cancers seem responsive to novel immunotherapies drugs. The aim of this review is to describe MSI and EBV positive gastric cancer's subgroups and their relationship with novel immunotherapy.

U2 - 10.3390/jcm9051427

DO - 10.3390/jcm9051427

M3 - Review article

C2 - 32403403

SN - 2077-0383

VL - 9

JO - Journal of Clinical Medicine

JF - Journal of Clinical Medicine

IS - 5

M1 - 1427

ER -

MSI and EBV Positive Gastric Cancer's Subgroups and Their Link With Novel Immunotherapy

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this